Sunday
09.27.2020
4:31 AM
Login form
Search
Calendar
«  May 2020  »
SuMoTuWeThFrSa
     12
3456789
10111213141516
17181920212223
24252627282930
31
Entries archive

My site

Main » 2020 » May » 06

New models provide a comprehensive solution including property and automobile across 17 European countries

NEWARK, Calif.-Wednesday 6 May 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- RMS, the leading global risk modeling and analytics firm, announced today at its annual Exceedance conference the release of new European Severe Convective Storm (EU SCS) High Definition Models. The models represent 50,000 years of simulation of hail and straight-line wind and tornado risk and include all key lines of business -- including automobile and property. In addition, the models cover 17* countries in Europe, complementing the RMS European climate hazard model suite.

Severe convective storms in Europe generally occur within the mid-latitudes in summer and can cause extensive loss to vehicles and property. Sometimes viewed as an attritional peril, severe convective storm risk is often managed using historical experience, despite incomplete observational reporting. Recent events ... Read more »

Views: 11 | Added by: africa-live | Date: 05.06.2020 | Comments (0)

Leading food manufacturer in Mexico optimizes costs and maximizes the lifespan and value of their mission-critical SAP system

 

LAS VEGAS-Tuesday 5 May 2020 [ AETOS Wire ]

 

(BUSINESS WIRE)-- ... Read more »

Views: 19 | Added by: africa-live | Date: 05.06.2020 | Comments (0)

• Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints

ST GALLEN, Switzerland-Tuesday 5 May 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Regulatory News:

Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anaemia due to Chronic Kidney Disease (CKD) in adult dialysis-dependent patients (DD-CKD). Upon successful completion of its phase-III program, which includes Akebia’s studies of vadadustat for the treatment of anemia due to CKD in non-dialysis patients, Akebia plans to submit a New Drug Application (NDA) for vadadustat for the treatment of anemia due to CKD in dialysis ... Read more »

Views: 11 | Added by: africa-live | Date: 05.06.2020 | Comments (0)

Study Finds Noninvasive, Continuous Masimo PVi® Monitoring More Valuable Than Central Venous Pressure Measurement for Guiding Fluid Management During Surgery

NEUCHATEL, Switzerland-Tuesday 5 May 2020 [ AETOS Wire ]

 

(BUSINESS WIRE)-- Masimo (NASDAQ: MASI ... Read more »

Views: 16 | Added by: africa-live | Date: 05.06.2020 | Comments (0)